Aspirin: Recent advances in cardiovascular prevention;L'aspirine: Acquisitions récentes en prévention cardiovasculaire

Revue Medicale de Liege

Volumn 59, Issue 12, 2004, Pages 695-703

  Kulbertus, H ^a,b  

^a ULg   (Belgium)

^b NONE   (Belgium)

Author keywords

Aspirin; Cardiovascular diseases; Clopidogrel; Primary prevention; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 1 INHIBITOR; PYRIDINE DERIVATIVE; TICLOPIDINE;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; HIGH RISK PATIENT; HUMAN; INDIGESTION; LIVER DYSFUNCTION; NAUSEA; RASH; REVIEW; SIDE EFFECT; VOMITING;

EID: 12344270739     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Abel B.- Aspirin: Old standby is the new wonder drug. http://healthlink.mcw.edu/article/1031002387.html consulté le 14/11/2004
2. Mahmud S, Franco E, Aprikian A.- Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and analysis. Br J Cancer, 2004, 90, 93-99.
3. Dubois RN.- Aspirin and breast cancer prevention. JAMA, 2004, 291, 2488-2489.
4. Chang ET, Zheng T, Weir EG, et al.- Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. J Natl Cancer Inst, 2004, 96, 305-315.
5. Hur C, Nishioka NS, Gazelle GS.- Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst, 2004, 96, 316-325.
6. Suh O, Mettlin C, Petrelli NJ.- Aspirin use, cancer, and polyps of the large bowel. Cancer, 1993, 72, 1171-1177.
7. Asano TK, McLeod RS.- Cochrane Data base Syst Rev, 2004, 2, CD004079.
8. Etminan M, Gill S, Samii A.- Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease; systematic review and meta-analysis of observational studies. BMJ, 2003, 327, 128
9. Patrono C.- Aspirin as an antiplatelet drug. N Engl J Med, 1994, 330, 1287-1294.
10. Awtry EH, Loscalzo J.- Aspirin. Circulation, 2000, 101, 1206-1218.
11. Patrono C, Patrignani P, Garcia-Rodriguez AG.- Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. JCI, 2001, 108, 7-13.
12. Altman R, Luciardi HL, Muntaner J, et al.- The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thrombosis Journal, 2004, 2, 1. Disponible sur http://www.thrombosisjournal.com/content/2/1/1.
13. FitzGerald GA, Lupinetti M, Charman SA, et al.- Pre-systemic acetylation of platelets by aspirin: reduction in the rate of drug delivery to improve biochemical selectivity to thromboxane A2. J Pharmacol Exp Ther, 1991, 259, 1043-1049.
14. Craven LL.- Acetylsalicylic acid, possible prevention of coronary thrombosis. Ann West Med Surg, 1950, 4, 95-96.
15. Antithrombotic Trialists' Collaboration.- Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002, 324, 71-86.
16. Steering Committee of the Physicians' Health Study Research Group.- Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med, 1989, 321, 129-135.
17. Sanmunganathan PS, Gharamani P, Jackson PR, et al.- Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart, 2001, 85, 1837-1847.
18. Hayden M, Pignone M, Phillips Ch et al.- Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med, 2002, 136, 161-172.
19. Collaborative Group of the Primary Prevention Project.- Low dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet, 2001, 357, 89-95.
20. Pearson ThA, Blair StN, Daniels StR, et al.- AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation, 2002, 106, 388-391.
21. US Preventive Services Task Force.- Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Ann Intern Med, 2002, 136, 157-160.
22. The Task Force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology.- Expert consensus document on the use of antiplatelets agents. Eur Heart J, 2004, 25, 166-181.
23. Anderson KM, Wilson PW, Odell PM, et al - An updated coronary risk profile; A statement for health professionals. Circulation, 1991, 83, 356-362.
24. Conroy RM, Pyörälä K, Fitzgerald AP, et al.- on behalf of the SCORE project group. Estimation often year risk of fatal cardiovascular disease ine Europe: the SCORE project. Eur Heart J, 2003, 24, 987-1003.
25. Guidelines Committee.- 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 2003, 21, 1011-1053.
26. American Diabetes Association.- Aspirin therapy in diabetes. Diabetes Care, 2002, 25, suppl. 1, Sè!-S79.
27. AHA guidelines.- Evidence-based guidelines for cardiovascular disease prevention in women. Circulation, 2004, 109, 672-693.
28. Hansson L, Zanchetti A, Carruthers SG, et al.- for the HOT study group.- Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension; principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 1998, 351, 1755-1762.
29. Lauer MS.- Clinical Practice. Aspirin use for primary prevention of coronary events. N Engl J Med, 2002, 346, 1468-1474.
30. Thomann P, Wölke E, Degen J, et al.- Relative bioavailability of acetylsalicylic acid from enteric coated rablets (100 and 300 mg) in comparison to the standard plain tablets with 100 and 300 mg aspirin. Eur J Clin Pharmaco, 1994, 47, A117.
31. MacDonald TM., Wei L.- Effect of ibuprofen on cardioprotective effect of aspirin. Lancet, 2003, 361, 573-574.
32. Teo KK, Yusuf S, Pfeffer M, et al.- Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet, 2002, 360, 1037-1043.
33. Guazzi M, Brambilla R, Reina G, et al.- Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure. A dose-related adverse effect of aspirin. Arch Intern Med, 2003, 163, 1574-1579.
34. Hennekens ChH, Sacks FM, Tonkin A, et al.- Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease. Arch Intern Med, 2004, 164, 40-44.
35. Quinn MJ, Fitzgerald DJ.- Ticlopidine and clopidogrel. Circulation, 1999, 100, 1667-1672.
36. CAPRIE Steering Committe.- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996, 348, 1329-1339.
37. Peters RJ, Mehta SR, Fox KAA, et al., for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators.- Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes. Circulation, 2003, 108, 1682,1687.
38. Jneid H, Bhatt DL Corti R et al.- Aspirin and clopidogrel in acute coronary syndromes. Therapeutic insights from the CURE study. Arch Intern Med, 2003, 163, 1145-1153.
39. Mehta SR, Yusuf Speters RJ, et al.- Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358, 527-533.
40. Stables RH.- Commentary. Clopidogrel in invasive management of non-ST-elevation ACS. Lancet, 2001, 358, 527-530.
41. Steinhubl StR, Berger PB, Tift Mann III J et al., for the CREDO investigators.- Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA, 2002, 288, 2411-2420.
42. Diener HC, Bogousslavsky J, Brass LM, et al.- on behalf of the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet, 2004, 364, 331-337.
43. Hennekens ChH, Schror K, Weisman St, et al.- Terms and conditions. Semantic complexity and aspirin resistance. Circulation, 2004, 110, 1706-1708.
44. Cattaneo M.- Aspirin, and clopidogrel. Efficacy,safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol, 2004, 24, 1980-1987.
45. Hankey GJ, Eikelboom JW.- Aspirin resistance. BMJ, 2004, 328, 477-479.
46. Lau WC, Gurbel PA, Watkins PB, et al.- Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation, 2004, 109, 166-171.
47. Schafer AI.- Genetic and acquired determinants of individual variability of response to antiplatelet drugs. Circulation, 2003, 108, 910-911.
48. Gaspoz JM, Coxson PG, Goldman PA, et al.- Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med, 2002, 346, 1800-1806.
49. Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CUARlSMA).http://www.clinicaltrials.gov/ct/show/ NCT000508117. Consulté le 18 novembre 2004.